Sientra CEO sends letter to surgeons saying implants are safe
Sientra CEO Hani Zeini sent another letter to plastic surgeons to reassure them that its products are safe. Sientra, a Goleta-based breast implant manufacturer, saw shares drop sharply over the past few months from a high of $23.75 on July 23. In recent weeks the stock fell from $20.58 on Sept. 23 to a close Read More →
Read More →
IQMS growing rapidly, hiring more workers in Paso Robles
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →U.K. crackdown sinks Sientra stock price
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Merged Ryland Group and Standard Pacific trading as CalAtlantic Group
CalAtlantic Group, the new homebuilding company formed in the merger between Ryland Group and Standard Pacific, traded under its new symbol CAA on Oct. 1 on the New York Stock Exchange. Now that the $5.2 billion “merger of equals” between the Westlake-based and Irvine-based homebuilders, respectively, has gone through, the new company has become the Read More →
Read More →Cal Amp’s second quarter earnings beat analyst estimates
Oxnard-based Cal Amp, which makes products for the wireless sector, beat analyst estimates on Oct. 1 when it reported second quarter 2016 results. Cal Amp posted earnings of 27 cents per share, beating analyst estimates of 26 cents per share. Analysts expected Cal Amp’s revenues to be around $68 million, but the company beat those Read More →
Read More →European regulators have good news for Amgen on cancer drugs
One of the world’s most expensive cancer drugs got conditional approval from European regulators on Sept. 25. Europeans granted Thousand Oaks-based Amgen conditional approval of its rare blood cancer drug Blincyto and gave a positive evaluation of Amgen’s multiple-myeloma drug Kyprolis. Blincyto is an immunotherapy that is designed to treat a rare form of leukemia Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
